Free Trial

Sera Prognostics Q2 2024 Earnings Report

Sera Prognostics logo
$4.12 -0.15 (-3.51%)
As of 02/21/2025 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.34

Sera Prognostics Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Sera Prognostics Earnings Headlines

The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
Sera Prognostics CFO sells $27,090 in stock
Sera Prognostics CEO sells $64,463 in stock
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat